EIT Pharma to Sponsor and Present at the 2026 Delta Cure International Meeting

EIT Pharma will present new analyses from the phase 3 D-LIVR trial of investigational lonafarnib at the October 15–16, 2026, Delta Cure International Meeting in Milan. The FDA accepted the company’s New Drug Application for lonafarnib earlier this year; the therapy remains unapproved, and its safety and efficacy have not been established.

Analysis

The event is a low-information catalyst until the data are public: the release previews analyses, not their results. The key value question is whether histologic improvement and post-treatment response strengthen the clinical case beyond changes in viral or liver-enzyme markers—and whether benefit persists after dosing stops. These distinctions could affect FDA confidence, labeling, and commercial differentiation, but the release provides no effect sizes, safety detail, or regulatory timing to underwrite a valuation change.

For the October 15–16 meeting, expect any reaction to hinge on whether the presentations add genuinely new, durable evidence; the announced topics alone are not evidence of efficacy. Over 1–3 months, FDA feedback or a review milestone would matter more than conference visibility. Over 6–18 months, commercial prospects depend on approval, usable labeling, safety/tolerability, and market access. Oral administration may be a convenience advantage, but it does not by itself establish superiority to existing HDV treatment options, including bulevirtide in Europe.

The contrarian risk is treating NDA acceptance as a regulatory endorsement: it is a review step, not approval. Conversely, if durable histologic benefit is convincing and safety supports long-term use, the market may underweight the value of an oral option in a serious, underserved disease. EIT Pharma has no ticker in the supplied identity data, and the article does not establish a public-market exposure or enough commercial inputs to size the opportunity.

Key Decisions for Investors

• No direct equity trade on this release: EIT Pharma has no supplied ticker, and the announcement contains no outcome data. Treat the meeting as a watch item, not a buy signal.
• On October 16, assess the actual effect sizes, confidence intervals, safety findings, and 24-week post-treatment results. Verify whether histologic changes are clinically meaningful and durable rather than relying on company framing.
• Track FDA review milestones and any requests for additional analyses or trials. A delay, restrictive proposed label, or safety concern would falsify the constructive regulatory thesis; acceptance of the NDA alone does not validate it.
• Before assigning commercial value, verify addressable U.S. patients, treatment duration, pricing/access assumptions, and comparative data versus available HDV therapies. Without these inputs, avoid extrapolating the oral-route advantage into a revenue forecast.